CN101970402B - 吡咯烷化合物 - Google Patents
吡咯烷化合物 Download PDFInfo
- Publication number
- CN101970402B CN101970402B CN2009801079412A CN200980107941A CN101970402B CN 101970402 B CN101970402 B CN 101970402B CN 2009801079412 A CN2009801079412 A CN 2009801079412A CN 200980107941 A CN200980107941 A CN 200980107941A CN 101970402 B CN101970402 B CN 101970402B
- Authority
- CN
- China
- Prior art keywords
- compound
- group
- alkyl
- alkyl group
- pyrrolidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC*C(*)(*(C)*C(*)(*)C(C)(C)C(C)(*)*(C)C(*)=O)*(C)C(N(CC(C1)F)C1C#N)=O Chemical compound CC*C(*)(*(C)*C(*)(*)C(C)(C)C(C)(*)*(C)C(*)=O)*(C)C(N(CC(C1)F)C1C#N)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3387708P | 2008-03-05 | 2008-03-05 | |
| US61/033,877 | 2008-03-05 | ||
| PCT/US2009/035111 WO2009111239A2 (en) | 2008-03-05 | 2009-02-25 | Pyrrolidine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101970402A CN101970402A (zh) | 2011-02-09 |
| CN101970402B true CN101970402B (zh) | 2013-12-18 |
Family
ID=41054296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801079412A Active CN101970402B (zh) | 2008-03-05 | 2009-02-25 | 吡咯烷化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8022096B2 (enExample) |
| EP (1) | EP2252582B1 (enExample) |
| JP (1) | JP5586484B2 (enExample) |
| KR (1) | KR101634656B1 (enExample) |
| CN (1) | CN101970402B (enExample) |
| AU (1) | AU2009222198B2 (enExample) |
| BR (1) | BRPI0906094B8 (enExample) |
| CA (1) | CA2717518C (enExample) |
| ES (1) | ES2515194T3 (enExample) |
| MY (1) | MY155630A (enExample) |
| NZ (1) | NZ587911A (enExample) |
| RU (1) | RU2494094C2 (enExample) |
| TW (1) | TWI385163B (enExample) |
| WO (1) | WO2009111239A2 (enExample) |
| ZA (1) | ZA201006329B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| IN2015DN03795A (enExample) | 2012-10-24 | 2015-10-02 | Inserm Inst Nat De La Santé Et De La Rech Médicale | |
| EP3116469B1 (en) | 2014-03-10 | 2018-10-03 | Mary Kay, Inc. | Skin lightening compositions |
| CN104447479B (zh) * | 2015-01-13 | 2016-03-23 | 佛山市赛维斯医药科技有限公司 | 含金刚烷和酰胺类衍生物、其制备方法和用途 |
| CN104447478B (zh) * | 2015-01-13 | 2016-04-13 | 佛山市赛维斯医药科技有限公司 | 一种含腈基金刚烷和酰胺结构的衍生物、其制备方法和用途 |
| CN104529855B (zh) * | 2015-01-13 | 2016-04-13 | 佛山市赛维斯医药科技有限公司 | 一种含羟基金刚烷和酰胺结构的衍生物、其制备方法和用途 |
| CN104496877B (zh) * | 2015-01-13 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一种腈基金刚烷酰胺衍生物、其制备方法和用途 |
| CN104478778B (zh) * | 2015-01-13 | 2016-03-16 | 佛山市赛维斯医药科技有限公司 | 金刚烷酰胺类衍生物、其制备方法和用途 |
| US10426818B2 (en) | 2015-03-24 | 2019-10-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
| CN118047708A (zh) * | 2019-12-31 | 2024-05-17 | 石药集团中奇制药技术（石家庄）有限公司 | 一种二肽基肽酶iv抑制剂的晶型及其制备方法和用途 |
| CN114641277B (zh) * | 2019-12-31 | 2023-06-13 | 石药集团中奇制药技术（石家庄）有限公司 | 一种二肽基肽酶4抑制剂的药物组合物及其制备方法和应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1735605A (zh) * | 2002-11-07 | 2006-02-15 | 麦克公司 | 苯丙氨酸衍生物作为二肽基肽酶抑制剂用于治疗或预防糖尿病 |
| CN1942186A (zh) * | 2004-03-09 | 2007-04-04 | 国家卫生研究院 | 吡咯烷化合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2293651T3 (es) * | 1995-11-28 | 2008-03-16 | Cephalon, Inc. | Inhibidores de cisteina y serina proteasas derivados de aminoacidos d. |
| JP2000264882A (ja) * | 1999-03-18 | 2000-09-26 | Nippon Shokubai Co Ltd | 有機アミド化合物およびその製造方法 |
| GB9928330D0 (en) * | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
| TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| MXPA05004890A (es) | 2002-11-07 | 2005-07-22 | Merck & Co Inc | Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevencion de diabetes. |
| JP2004203526A (ja) | 2002-12-24 | 2004-07-22 | Sharp Corp | 記録装置 |
| DK1595866T3 (en) | 2003-01-31 | 2016-08-22 | Sanwa Kagaku Kenkyusho Co | Cyanopyrrolidines suitable for the treatment of inter alia metabolism syndrome |
| EP1625122A1 (en) | 2003-05-14 | 2006-02-15 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US20070093492A1 (en) * | 2004-03-09 | 2007-04-26 | Weir-Torn Jiaang | Pyrrolidine derivatives |
| EP1760076A1 (en) * | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
-
2009
- 2009-02-25 RU RU2010140627/04A patent/RU2494094C2/ru active
- 2009-02-25 US US12/392,590 patent/US8022096B2/en active Active
- 2009-02-25 CN CN2009801079412A patent/CN101970402B/zh active Active
- 2009-02-25 KR KR1020107021993A patent/KR101634656B1/ko active Active
- 2009-02-25 NZ NZ587911A patent/NZ587911A/en unknown
- 2009-02-25 JP JP2010549729A patent/JP5586484B2/ja active Active
- 2009-02-25 BR BRPI0906094A patent/BRPI0906094B8/pt active IP Right Grant
- 2009-02-25 WO PCT/US2009/035111 patent/WO2009111239A2/en not_active Ceased
- 2009-02-25 EP EP09718154.9A patent/EP2252582B1/en active Active
- 2009-02-25 ES ES09718154.9T patent/ES2515194T3/es active Active
- 2009-02-25 AU AU2009222198A patent/AU2009222198B2/en active Active
- 2009-02-25 MY MYPI2010004155A patent/MY155630A/en unknown
- 2009-02-25 CA CA2717518A patent/CA2717518C/en active Active
- 2009-03-03 TW TW098106781A patent/TWI385163B/zh active
-
2010
- 2010-09-03 ZA ZA2010/06329A patent/ZA201006329B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1735605A (zh) * | 2002-11-07 | 2006-02-15 | 麦克公司 | 苯丙氨酸衍生物作为二肽基肽酶抑制剂用于治疗或预防糖尿病 |
| CN1942186A (zh) * | 2004-03-09 | 2007-04-04 | 国家卫生研究院 | 吡咯烷化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2494094C2 (ru) | 2013-09-27 |
| ZA201006329B (en) | 2011-05-25 |
| BRPI0906094B8 (pt) | 2021-05-25 |
| ES2515194T3 (es) | 2014-10-29 |
| BRPI0906094B1 (pt) | 2019-11-12 |
| AU2009222198B2 (en) | 2014-05-08 |
| RU2010140627A (ru) | 2012-04-10 |
| CA2717518A1 (en) | 2009-09-11 |
| CA2717518C (en) | 2017-03-21 |
| BRPI0906094A2 (pt) | 2016-07-05 |
| JP5586484B2 (ja) | 2014-09-10 |
| EP2252582A4 (en) | 2012-03-07 |
| US20090227569A1 (en) | 2009-09-10 |
| WO2009111239A2 (en) | 2009-09-11 |
| WO2009111239A3 (en) | 2009-10-29 |
| MY155630A (en) | 2015-11-13 |
| JP2011513410A (ja) | 2011-04-28 |
| AU2009222198A1 (en) | 2009-09-11 |
| TWI385163B (zh) | 2013-02-11 |
| EP2252582B1 (en) | 2014-07-23 |
| TW200938530A (en) | 2009-09-16 |
| NZ587911A (en) | 2012-02-24 |
| US8022096B2 (en) | 2011-09-20 |
| HK1149261A1 (en) | 2011-09-30 |
| KR101634656B1 (ko) | 2016-06-29 |
| CN101970402A (zh) | 2011-02-09 |
| EP2252582A2 (en) | 2010-11-24 |
| KR20100129754A (ko) | 2010-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101970402B (zh) | 吡咯烷化合物 | |
| AU2005221678B2 (en) | Pyrrolidine compounds | |
| JP4559737B2 (ja) | Ｎ−アミノアセチル−ピロリジン−２−カルボニトリルおよびｄｄｐ−ｉｖ阻害剤としてのその使用 | |
| WO2004080966A1 (ja) | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 | |
| CN101443322A (zh) | 含氮杂环衍生物及含有该衍生物作为活性成分的药物 | |
| JP2005511541A (ja) | プロリン後切断プロテアーゼの阻害剤 | |
| JP2008031064A (ja) | ジアシルピペラジン誘導体 | |
| WO2006073167A1 (ja) | ピロリジン誘導体 | |
| RU2396257C2 (ru) | Производные 4-аминопиперидина | |
| WO2005077900A1 (ja) | ビシクロアミド誘導体 | |
| US7425633B2 (en) | Pyrrolidine compounds | |
| JPWO2004101514A1 (ja) | シアノフルオロピロリジン誘導体 | |
| AU2006222232A1 (en) | 3,4,5-substituted piperidine compounds | |
| JP2008063256A (ja) | β‐アミノ酸誘導体 | |
| WO2005073186A1 (ja) | ピロリジン誘導体 | |
| CN101300226B (zh) | 对组蛋白脱乙酰酶具有抑制活性的烷基氨甲酰基萘氧基辛烯酰基羟基酰胺衍生物及其制备方法 | |
| HK1149261B (en) | Pyrrolidine derivatives | |
| US20090281161A1 (en) | Organic Compounds | |
| JP2009539904A (ja) | レニン阻害剤としてのピロリジン化合物 | |
| JP2007031396A (ja) | ピロリジン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1149261 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20110209 Assignee: GENOVATE BIOTECHNOLOGY Co.,Ltd. Assignor: National Health Research Institutes Contract record no.: 2014990000046 Denomination of invention: 2-alkylpyrrolidines Granted publication date: 20131218 License type: Exclusive License Record date: 20140123 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1149261 Country of ref document: HK |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20110209 Assignee: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) Co.,Ltd. Assignor: GENOVATE BIOTECHNOLOGY Co.,Ltd. Contract record no.: 2015990000769 Denomination of invention: 2-alkylpyrrolidines Granted publication date: 20131218 License type: Common License Record date: 20150827 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20110209 Assignee: CSPC PHARMACEUTICAL GROUP OUYI PHARMA Co.,Ltd. Assignor: GENOVATE BIOTECHNOLOGY Co.,Ltd. Contract record no.: X2023990000315 Denomination of invention: Pyrrolidine compounds Granted publication date: 20131218 License type: Common License Record date: 20230324 |
|
| EE01 | Entry into force of recordation of patent licensing contract |